MLYS · Mineralys Therapeutics, Inc.
$26.71
-0.96% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-13.0
Dividend yield
—
Beta
0.65
Avg volume
1M
Employees
0K
2D change
1.87%
5D change
0.78%
10D change
0.44%
30D change
1.99%
60D change
-13.62%
MTD change
1.19%
YTD change
-25.02%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — MLYS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-04-27
Latest call per bank · past 12 months
Bank of America
Buy$51.00
+90.9% vs priceWells Fargo
Overweight$55.00
+105.9% vs priceGoldman Sachs
Buy$52.00
+94.7% vs priceJefferies
Hold$26.00
-2.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-04-27 | TD Cowen | Initiates | Buy | $0.00 |
| 2026-03-13 | Bank of America | Maintains | Buy | $46.00 → $51.00 |
| 2025-12-19 | Stifel | Maintains | Buy | $45.00 → $52.00 |
| 2025-11-12 | HC Wainwright & Co. | Maintains | Buy | $52.00 → $56.00 |
| 2025-11-11 | Wells Fargo | Maintains | Overweight | $50.00 → $55.00 |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy | $42.00 → $52.00 |
| 2025-09-11 | Wells Fargo | Maintains | Overweight | $26.00 → $50.00 |
| 2025-09-09 | Goldman Sachs | Maintains | Buy | $32.00 → $52.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.4% below the 50-day MA ($27.05).
- Price vs 200-day MA: Trading 15.3% below the 200-day MA ($31.82).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.13) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($12.87) and high ($47.33).
MLYS Price Chart
Loading chart for MLYS…
Fundamentals
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.